Sernova Biotherapeutics Inc
SVA.TO
TSX
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.22% | 8.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.64% | -9.70% | |||
| Operating Income | -7.64% | 9.70% | |||
| Income Before Tax | -32.99% | -9.31% | |||
| Income Tax Expenses | -- | -34.09% | |||
| Earnings from Continuing Operations | -37.09% | -8.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -37.09% | -8.69% | |||
| EBIT | -7.64% | 9.70% | |||
| EBITDA | -7.67% | 7.71% | |||
| EPS Basic | -31.37% | -6.25% | |||
| Normalized Basic EPS | -27.27% | -6.45% | |||
| EPS Diluted | -31.37% | -6.25% | |||
| Normalized Diluted EPS | -27.27% | -6.45% | |||
| Average Basic Shares Outstanding | 4.38% | 2.34% | |||
| Average Diluted Shares Outstanding | 4.38% | 2.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||